Researchers develop photoactivatable nanomedicine for the treatment of age-related macular ...
Phys.org· 7 days agoThrough the intravenous injection of the nanomedicine and application of light irradiation to...
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration...
Nature· 4 days agoIntravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative age-related macular
Dr. ROACH: Vitamins for macular degeneration coincide with new cramps | Robesonian
The Robesonian· 5 days agoROACH: I have been told at the age of 70 that I am in the early stages of the eye disease macular ...
RetinAI Medical joins non-profit macular degeneration initiative
FierceBiotech· 5 days agoRetinAI Medical, a Swiss developer of software for accelerating retinal disease R&D, has
Is A Retinal Picture Worth A Thousand Diagnoses?
Forbes· 2 days agoThe human eye is a marvelous work of art. Any deviation from its optimal state can lead to an array of eye diseases, most of which can be diagnosed and...
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
InvestorPlace· 10 hours agoIf the first rule in the film “Fight Club” is to not talk about fight club, then the same rule...
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel...
Benzinga· 10 hours agoNEW YORK, Dec. 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds
RetinAI Joins Forces with Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium to...
Morningstar· 5 days agoBERN, Switzerland and BOSTON, Nov. 29, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI), announces that they are now joining
Foundation Fighting Blindness Appoints Jeff Klaas as Chief Strategy and Innovation Officer
Valley News Live· 5 days agoKlaas brings over twenty years of experience to lead strategies aimed at elevating engagement and...
Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 9.3% in November
ETF DAILY NEWS· 9 hours agoCoherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling ...
Yahoo Web Search
Trending Now
